IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Exhibits Extended In Vivo Half-Life and Synergistic Antiviral Effect When Combined with Neutralizing Antibodies

IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Exhibits Extended In Vivo Half-Life and Synergistic Antiviral Effect When Combined with Neutralizing Antibodies

The peptide-based pan-coronavirus fusion inhibitor EK1 is in phase III clinical trials, and it has, thus far, shown good clinical application prospects against SARS-CoV-2 and its variants. To further improve its in vivo long-acting property, we herein developed an Fc-binding strategy by conjugating...

Full description

Bibliographic Details
Main Authors: Xiaojie Su, Ziqi Huang, Wei Xu, Qian Wang, Lixiao Xing, Lu Lu, Shibo Jiang, Shuai Xia
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Biomolecules
Subjects:
human coronavirus
fusion inhibitor
IgG-binding peptide
long-acting strategy
half-life
neutralizing antibodies
Online Access:https://www.mdpi.com/2218-273X/13/9/1283

Internet

https://www.mdpi.com/2218-273X/13/9/1283

Similar Items